How is NGS-based comprehensive genomic profiling transforming oncology IVD?
Comprehensive genomic profiling panels detecting hundreds to thousands of somatic mutations, copy number alterations, and structural variants simultaneously from a single tumour tissue or liquid biopsy specimen are replacing sequential single-gene and small-panel mutation testing in advanced solid tumour oncology diagnostics, enabling a complete tumour genomic landscape characterisation required for precision oncology treatment matching including targeted therapy selection, clinical trial eligibility, and tumour mutational burden/microsatellite instability assessment for immunotherapy prediction. U.S. CMS reimbursement approval for FDA-approved companion diagnostic CGP panels including Foundation Medicine FoundationOne CDx and Guardant Health liquid biopsy tests has accelerated CGP adoption at oncology treatment centres, sustaining NGS-based IVD reagent and instrument revenue at a materially faster growth rate than conventional single-analyte oncology biomarker testing.

How is CRISPR-based diagnostic technology differentiating from PCR at the point of care?
CRISPR-based diagnostic platforms — including Sherlock Biosciences SHERLOCK and Mammoth Biosciences DETECTR systems — use CRISPR-Cas12 or Cas13 enzymes programmed with guide RNA sequences to detect specific pathogen nucleic acid sequences and generate a fluorescent or lateral flow strip signal upon target recognition, providing isothermal amplification and detection in a single reaction step without the thermocycling equipment required by PCR. CRISPR diagnostic platforms operating at isothermal conditions can be implemented in simple battery-powered devices suitable for field deployment without laboratory infrastructure, enabling infectious disease nucleic acid testing in low-resource settings, point-of-care clinical environments, and decentralised food and environmental safety testing applications that PCR equipment cost and complexity cannot reach.

What is sustaining rapid immunoassay POCT expansion in emergency and primary care settings?
Point-of-care immunoassay platforms — delivering troponin, BNP, D-dimer, influenza, RSV, strep A, COVID-19, CRP, and procalcitonin results from a single reader within 15 to 20 minutes from whole blood finger-prick or nasopharyngeal swab specimens at the emergency department, primary care clinic, or urgent care site — compress the diagnostic-to-treatment decision cycle that waiting for central laboratory results generates. Published time-to-treatment improvement studies at emergency departments deploying cardiac troponin POCT — enabling NSTEMI rule-in or rule-out decisions within 30 to 60 minutes of patient presentation above 4 to 6 hour central lab serial sampling protocols — are sustaining capital investment in POCT platform expansion at emergency care and acute medicine programmes.

How is liquid biopsy IVD technology advancing the non-invasive oncology diagnostics paradigm?
Liquid biopsy platforms detecting circulating tumour DNA, circulating tumour cells, or extracellular vesicles in peripheral blood provide a non-invasive alternative to tumour tissue biopsy for treatment selection, resistance mutation tracking, and minimal residual disease monitoring — enabling repeat longitudinal sampling that tissue biopsy costs and patient burden make impractical. FDA-approved companion diagnostic liquid biopsy assays for EGFR, BRAF, and KRAS mutation detection in non-small cell lung cancer, colorectal cancer, and melanoma treatment selection have established reimbursed clinical pathways that sustain commercial liquid biopsy IVD product adoption at oncology treatment centres.

What is driving mass spectrometry-based IVD adoption in clinical reference laboratory settings?
Liquid chromatography-tandem mass spectrometry platforms deployed in high-throughput clinical reference laboratory settings provide superior analytical specificity over immunoassay methods for hormones, immunosuppressant drugs, vitamin D metabolites, toxicology screening, and newborn screening analytes where antibody cross-reactivity in immunoassay formats generates false positive or false negative results with clinical management consequences. The growing recognition of immunoassay interference from heterophile antibodies, biotin, and rheumatoid factor sustaining LC-MS/MS method adoption at laboratories serving populations with high interference-prone specimen prevalence — transplant programmes, biotin supplement users — is driving mass spectrometry instrument investment at clinical reference and academic medical centre core laboratories.

Which IVD segments are growing fastest?
NGS-based CGP oncology companion diagnostics sustaining rapid revenue growth from reimbursement expansion, CRISPR diagnostic platform commercialisation in POCT and decentralised settings, liquid biopsy non-invasive oncology testing growing from FDA companion diagnostic approvals, and LC-MS/MS clinical reference laboratory adoption above immunoassay interference limitation are the four fastest-growing IVD segments.